So now that they have a partner for distribution how does this affect MSB
1. Exposure to patients provides trial opportunities -> lower cost trials -> lower cash burn
2. Exposure to practitioners -> no need for salesforce -> lower cash burn
3. Extra $110m USD not tied to just Rex-L but free deploy funds for Rem-L confirmatory trials
4. Extra exposure to other ortho indications beyond backpain -> increased market opportunities
Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group, page-190
-
- There are more pages in this discussion • 319 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |